Patents Assigned to OncoTracker, Inc.
  • Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
    Patent number: 11246876
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: February 15, 2022
    Assignee: OncoTracker, Inc.
    Inventor: James R. Berenson
  • ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS
    Publication number: 20200030343
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Application
    Filed: May 7, 2019
    Publication date: January 30, 2020
    Applicant: OncoTracker, Inc.
    Inventor: James R. BERENSON
  • Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
    Patent number: 10363260
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 30, 2019
    Assignee: OncoTracker, Inc.
    Inventor: James R. Berenson